OncoMatch/Clinical Trials/NCT06432036
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Is NCT06432036 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for stage i renal cell cancer.
This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Any prior radiation therapy to the abdomen, including localized radiation therapy to the index tumor
Cannot have received: systemic therapy for RCC
Exception: unless it is an observational study (non-interventional) or during a non-interventional follow-up stage of an interventional study, or prior randomization to this study
Concurrent treatment for RCC or treatment in the last 6 months in another clinical study
Lab requirements
Blood counts
hemoglobin ≥ 9.0 g/dl; absolute neutrophil count ≥ 1.5 x 10^9/l; absolute lymphocyte count ≥ 1.0 x 10^9/l; platelet count ≥ 75 x 10^9/l
Kidney function
glomerular filtration rate (gfr) ≥ 45 ml/min/1.73 m^2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify